1 |
Sandy J, Mushtaq A, Kawamura A, Sinclair J, Sim E, Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis : an enzyme which inactivates the antitubercular drug, isoniazid. J Mol Biol 2002;318:1071-83.
DOI
|
2 |
Dassault Systemes. BIOVIA, Discovery Studio Modeling Environment. Release 4.5. San Diego: Dassault Systemes; 2015.
|
3 |
Zhang Y, Heym B, Allen B, Young D, Cole S. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis . Nature 1992;358:591-3.
DOI
|
4 |
Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis . Science 1994;263:227-30.
DOI
|
5 |
Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis : 1998 update. Tuber Lung Dis 1998;79:3-29.
DOI
|
6 |
Payton M, Auty R, Delgoda R, Everett M, Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis : increased expression results in isoniazid resistance. J Bacteriol 1999;181:1343-7.
|
7 |
Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, et al. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol 2001;42:309-17.
DOI
|
8 |
Hickman D, Palamanda JR, Unadkat JD, Sim E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli . Biochem Pharmacol 1995;50:697-703.
DOI
|
9 |
Bhakta S, Besra GS, Upton AM, Parish T, Sholto-Douglas-Vernon C, Gibson KJ, et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J Exp Med 2004;199:1191-9.
DOI
|
10 |
Evans DA, Manley KA, Mc KV. Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485-91.
DOI
|
11 |
Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997;155:1717-22.
DOI
|
12 |
Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
DOI
|
13 |
Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005;49:1733-8.
DOI
|
14 |
Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis . Infect Genet Evol 2016;45:474-92.
DOI
|
15 |
World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth Global Report. The WHO/IAUTLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 2002-2007. Geneva: World Health Organization; 2008.
|
16 |
Winder F. Catalase and peroxidase in mycobacteria: possible relationship to the mode of action of isoniazid. Am Rev Respir Dis 1960;81:68-78.
DOI
|
17 |
Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-9.
DOI
|
18 |
Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256-61.
|
19 |
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
DOI
|
20 |
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-402.
DOI
|
21 |
Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013;69:1091-101.
DOI
|
22 |
Advanced Chemistry Development. ACD/ChemSketch, ver. 10.0. Toronto: Advanced Chemistry Development; 2006.
|
23 |
Abuhammad A, Lowe ED, McDonough MA, Shaw Stewart PD, Kolek SA, Sim E, et al. Structure of arylamine N-acetyltransferase from Mycobacterium tuberculosis determined by cross-seeding with the homologous protein from M. marinum: triumph over adversity. Acta Crystallogr D Biol Crystallogr 2013;69(Pt 8):1433-46.
DOI
|
24 |
Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 2007;282:30189-97.
DOI
|
25 |
Sali A. MODELLER: implementing 3D protein modeling. mc2, Vol. 2. San Diego: Molecular Simulations Inc.; 1995.
|
26 |
Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by geometry: , and deviation. Proteins 2003;50:437-50.
DOI
|
27 |
Krissinel E, Henrick K. Protein structure comparison in 3D based on secondary structure matching (PDBeFold) followed by alignment, scored by a new structural similarity function. In: Proceedings of the 5th International Conference on Molecular Structural Biology; 2003 Sep 3-7; Vienna, Austria; p.88.
|
28 |
Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995;245:43-53.
DOI
|
29 |
Accelrys Inc. Discovery studio, ver. 2. San Diego: Accelrys Inc.; 2007.
|
30 |
Abuhammad AM, Lowe ED, Fullam E, Noble M, Garman EF, Sim E. Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site. Protein Cell 2010;1:384-92.
DOI
|
31 |
Fullam E, Westwood IM, Anderton MC, Lowe ED, Sim E, Noble ME. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine Nacetyltransferase. J Mol Biol 2008;375:178-91.
DOI
|